About Valerion Therapeutics
Valerion Therapeutics is a Healthcare company based in Concord (United States) founded in 2002 by Timothy Harris. Delivering protein therapies using antibody-mediated delivery platform for the treatment of orphan genetic diseases. Valerion Therapeutics has raised $30 million across 5 funding rounds from investors including HHS, Alopexx and Sanofi Ventures. Its website valerion.com draws about 328 thousand monthly visits. Valerion Therapeutics offers products and services including VisionMaster Series, VisionMaster Max, VisionMaster Pro2, and VisionMaster Pro. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its legal entity is Valerion, Inc. Its competitors include Alnylam, Ultragenyx and MacroGenics; 3 of its 3 listed competitors have raised funding.
Company details
Valerion Therapeutics (formerly 43s Biosciences) is utilizing a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a well-known and broadly studied transport pathway. Its drug pipeline includes VAL-0620, a fusion protein of the platform delivery antibody 3E10 linked to MTM1 to treat myotubular myopathy. Myotubular myopathy is an x-linked congenital myopathy in which a deficiency of a single enzyme (MTM1) causes severe muscle disease. Also developing VAL-0411, a fusion protein of the proprietary delivery antibody 3E10 linked to MBNL1, the muscleblind protein necessary for correct mRNA activity in patients with myotonic dystrophy. Also developing drugs to treat Glycogen storage diseases such as Pompe Disease and Forbes-Cori
- Headquarters Concord, United States
- Founders Timothy Harris
- SectorsHealthcare
- Website category Computers Electronics and Technology · Consumer Electronics
- Website valerion.com
- Social LinkedIn Instagram YouTube
- Legal Name Valerion, Inc.
- Total Equity Funding$30M (USD)
in 5 rounds
- Latest Funding Round$10M (USD), Series B
Jun 2015
- InvestorsHHS
& 2 more
Products & Services of Valerion Therapeutics
Valerion Therapeutics offers a comprehensive portfolio of products and services, including VisionMaster Series, VisionMaster Max, VisionMaster Pro2, and VisionMaster Pro.
Offers cinematic-grade RGB laser projection for home entertainment.
Delivers high-brightness and contrast for large-screen viewing.
Features ProVision Engine for enhanced image quality.
Provides advanced performance with smart OS capabilities.
Apps and channels of Valerion Therapeutics
its YouTube channel ValerionTech has 1.3K subscribers.
Funding Insights of Valerion Therapeutics
Valerion Therapeutics has successfully raised a total of $30M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $10 million completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30M
- Total Rounds 5
- Last Round Series B — $10M
- Investors Count 3
All 5 funding rounds of Valerion Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2015 | $10M | Series B | – | – | |
| Mar 2012 | $20M | Series A | – | – | |
| Aug 2009 | $336,682 | Grant | – | – | |
| Jul 2009 | $336,682 | Grant | – | – | |
| Jun 2008 | Seed | – | – |
3 investors in total: 3 institutional.
Investors in Valerion Therapeutics
Valerion Therapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Alopexx and Sanofi Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in healthcare technology sectors are focused on by Alopexx. | 2011 | alopexx.com | Cambridge, United States | |
Life-Sciences focused Early stage Corporate VC Firm investing in the US | sanofiventures.com | Paris, France | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Valerion Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Valerion Therapeutics
1 people are tracked at Valerion Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Timothy Harris | Co-Founder | Leadership |
Complete people profiles for Valerion Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Valerion Therapeutics
3 dated milestones of Valerion Therapeutics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Valerion Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $10.0M.
Competitors of Valerion Therapeutics
Valerion Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and MacroGenics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| macrogenics.com | 2000 | Rockville, United States | $126.02M | 339 | A biopharmaceutical company focused on cancer therapeutics development. |
Detailed competitors of Valerion Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Valerion Therapeutics
The website of Valerion Therapeutics (valerion.com) receives about 328.2K visits a month and ranks #82,477 among all websites worldwide, #729 in Consumer Electronics.
- Monthly visits328.2K
▼ 37.7% vs previous month
- Unique visitors258.2K
per month
- Global rank#82,477
among all websites
- Category rank#729
Computers Electronics and Technology · Consumer Electronics
- Bounce rate43%
- Pages per visit3.8
- Average visit1 min 20 sec
- DevicesDesktop 21% · Mobile 79%
Websites whose visitors overlap most with Valerion Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
projectorjunkies.com | projectorjunkies.com | 100% | #433,515 | – | |
heimkinowelten.de | heimkinowelten.de | 98% | #318,154 | – | |
vividstormscreen.com | vividstormscreen.com | 86% | #270,164 | – | |
| awolvision.com | 84% | #169,052 | View details | ||
awolvision.de | awolvision.de | 80% | #640,132 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Valerion Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Valerion Therapeutics (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Valerion Therapeutics
Complete news archive for Valerion Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Valerion Therapeutics
Valerion Therapeutics was founded in 2002 and raised its 1st funding round 6 years after it was founded.
Valerion Therapeutics is headquartered in Concord, United States. It is registered at Concord, New Hampshire, United States.
Valerion Therapeutics is a funded company, having raised a total of $30M across 5 funding rounds to date.
Valerion Therapeutics (formerly 43s Biosciences) is utilizing a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a well-known and broadly studied transport pathway. Its drug pipeline includes VAL-0620, a fusion protein of the platform delivery antibody 3E10 linked to MTM1 to treat myotubular myopathy. Myotubular myopathy is an x-linked congenital myopathy in which a deficiency of a single enzyme (MTM1) causes severe muscle disease. Also developing VAL-0411, a fusion protein of the proprietary delivery antibody 3E10 linked to MBNL1, the muscleblind protein necessary for correct mRNA activity in patients with myotonic dystrophy. Also developing drugs to treat Glycogen storage diseases such as Pompe Disease and Forbes-Cori.
Valerion Therapeutics's top competitors include Alnylam, MacroGenics and Ultragenyx.
Valerion Therapeutics offers VisionMaster Series, VisionMaster Max, VisionMaster Pro2, and VisionMaster Pro.
Valerion Therapeutics has 3 investors. Key investors include HHS, Alopexx, and Sanofi Ventures.
Valerion Therapeutics operates through Valerion, Inc..
The website of Valerion Therapeutics receives about 328 thousand visits a month and ranks #82,477 among all websites worldwide.